Tirzepatide, a once-weekly GIP/GLP-1 receptor agonist, is a medicine used for weight reduction in adults with obesity. A new analysis of the SURMOUNT clinical trials reveals that the medicine, ...

Please provide your email address to receive an email when new articles are posted on . Of adults who did not lose 5% of their weight with tirzepatide at 12 weeks, 90% achieved 5% weight loss at 72 ...

Eli Lilly and Company, along with partner institutions in the US and United Kingdom, describe how short-term pharmacologic intervention does not appear to have lasting effects for most tirzepatide ...

In the context of the global obesity epidemic, the FDA approved several glucagon-like peptide-1 (GLP-1) receptor agonists (GPL-1RAs), such as liraglutide (Saxenda) and semaglutide (Ozempic, Wegovy) as ...

New study reveals semaglutide outperforms liraglutide in weight loss for obesity, highlighting key factors that contribute to significant weight reduction in patients. Study: One-Year Weight Reduction ...

Study reveals that GLP-1 therapy increases visceral adipose tissue metabolism, significantly contributing to weight loss in individuals with obstructive sleep apnea. Study: GLP-1 therapy increases ...